Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SELLAS Life Sciences Group, Inc. | b87734exv99w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 15, 2011
RXi PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 001-33958 | 20-8099512 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
60 Prescott Street
Worcester, Massachusetts 01605
Worcester, Massachusetts 01605
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (508) 767-3861
Not Applicable
Former name or former address, if changed since last report
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
| Item 2.02 Results of Operations and Financial Condition | ||||||||
| Item 9.01 Financial Statements and Exhibits | ||||||||
| Signature | ||||||||
| Index to Exhibits | ||||||||
| EX-99.1 | ||||||||
Table of Contents
| Item 2.02 | Results of Operations and Financial Condition. |
On August 15, 2011, RXi Pharmaceuticals Corporation (the “Company”) issued a press release
announcing the Company’s financial results and business developments for the quarter ended June 30,
2011. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and is incorporated
herein by reference.
The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall
not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such
information be deemed to be incorporated by reference in any subsequent filing by the Company under
the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of
such filing, except as specifically stated in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |||
| 99.1 | Press Release of RXi Pharmaceuticals Corporation dated August 15, 2011. |
|||
1
Table of Contents
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 15, 2011 | RXI PHARMACEUTICALS CORPORATION |
|||
| By: | /s/ Mark J. Ahn | |||
| Mark J. Ahn | ||||
| President and Chief Executive Officer | ||||
2
Table of Contents